These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 14829892)

  • 1. [Purification of antitoxic serums].
    AMOUREUX G; YEU F
    Ann Inst Pasteur (Paris); 1951 Feb; 80(2):165-74. PubMed ID: 14829892
    [No Abstract]   [Full Text] [Related]  

  • 2. [Purification and enzymatic disantigenization of antitoxic serums and plasmas. III. Theoretical evaluation of antitoxic and anaphylactic function of antitoxic serums and plasmas].
    CORDON F; MARTINEZ A
    Microbiol Esp; 1957; 10(1):69-98. PubMed ID: 13464448
    [No Abstract]   [Full Text] [Related]  

  • 3. [Purification and concentration of antitoxic plasmas. I. History, technics in industry and method used in Iran].
    DELSAL JL; CHAMSY HM
    Rev Immunol Ther Antimicrob; 1953; 17(3):110-34. PubMed ID: 13089273
    [No Abstract]   [Full Text] [Related]  

  • 4. [Contribution to the study of the relation between serum properdin and pyrogenic substances from purified antitoxic serums].
    Toma E; Szégli G; Gartner M; Negut M
    Arch Roum Pathol Exp Microbiol; 1964 Dec; 23(4):967-72. PubMed ID: 5836099
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation of the antitoxic power of anti-perfringens A serums; history].
    GUILLAUMIE M; KREGUER A; GEOFFROY M
    Ann Inst Pasteur (Paris); 1956 Mar; 90(3):265-75. PubMed ID: 13327474
    [No Abstract]   [Full Text] [Related]  

  • 6. [The problem of so-called agglutination of staphylococci with antitoxic serum; experimental studies related to the discussion of Dr. Lukas and Dr. Wagner].
    JOHANOVSKY J
    Cesk Epidemiol Mikrobiol Imunol; 1956 Jul; 5(4):213-20. PubMed ID: 13374753
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antitoxic power of types B and C antiperfringens serums].
    GUILLAUMIE M; KREGUER A; GEOFFROY M; VENTRE F
    C R Hebd Seances Acad Sci; 1957 Jul; 245(2):245-8. PubMed ID: 13461392
    [No Abstract]   [Full Text] [Related]  

  • 8. Purification and characterization of antitoxic proteins from the serum of Agkistrodon halys Pallas.
    Niu YP; Shao JY; Jiang YL
    Toxicon; 2007 Sep; 50(3):322-9. PubMed ID: 17512568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mathematical model of the infection process in diphtheria for determining the therapeutic dose of antitoxic anti-diphtheria serum].
    Kolibo DV; Romaniuk SI
    Ukr Biokhim Zh (1999); 2001; 73(2):144-51. PubMed ID: 11642038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CONTRIBUTION TO THE PROBLEM OF DETERMINATION OF THE DEGREE OF DESPECIATION OF PURIFIED ANTITOXIC SERUMS].
    SZEGLI G; TOMA E; GARTNER M
    Arch Roum Pathol Exp Microbiol; 1963 Sep; 23():791-6. PubMed ID: 14165862
    [No Abstract]   [Full Text] [Related]  

  • 11. An Examination into the Value of Certain Antiseptics Used for the Preservation of Antitoxic and Other Immune Serums.
    McFarland J
    Public Health Pap Rep; 1902; 28():506-8. PubMed ID: 19601088
    [No Abstract]   [Full Text] [Related]  

  • 12. Antitoxic Serums.
    Houghton EM
    Buffalo Med J; 1898 Jul; 37(12):881-891. PubMed ID: 36887985
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation of the antitoxic power of anti-perfringens B, C & D type serums. I. Properties of toxins used to titrate these immune sera].
    GUILLAUMIE M; KREGUER A; GEOFFROY M; VENTRE F
    Rev Immunol Ther Antimicrob; 1957; 21(4):293-309. PubMed ID: 13506328
    [No Abstract]   [Full Text] [Related]  

  • 14. [Isolation of antitoxic fractions from serums of guinea pigs immunized with diphtheria toxoid].
    Aleksandrowicz J; Mierzejewska H
    Med Dosw Mikrobiol; 1970; 22(1):75-82. PubMed ID: 5445852
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the antitoxic power of anti-perfringens B, C & D type serums. II. Results of comparative titrations with various homologus perfringens toxins.
    GUILLAUMIE M; KREGUER A; GEOFFROY M; VENTRE F
    Rev Immunol Ther Antimicrob; 1957; 21(4):310-26. PubMed ID: 13506329
    [No Abstract]   [Full Text] [Related]  

  • 16. [Passive immunity obtained by different routes of administration of purified and unpurified antitoxic serums].
    Devissaguet A; Devissaguet JP; Plissier M
    Ann Pharm Fr; 1973 Apr; 31(4):293-304. PubMed ID: 4794032
    [No Abstract]   [Full Text] [Related]  

  • 17. [Azo-binding of antitoxic immune sera. III. Azo-proteins].
    ZIMMERMANN G
    Z Immun exp ther; 1958 Sep; 116(3):219-27. PubMed ID: 13604524
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clarification of therapeutic and immunogenic values of sero-antitoxic therapy of tetanus].
    KATIC R
    Vojnosanit Pregl; 1960 Mar; 17():229-35. PubMed ID: 14404721
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum effects of mitogenic reactivity in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Technical considerations and lack of correlation with anti-lymphocyte antibodies.
    Horwitz DA; Garrett MA; Craig AH
    Clin Exp Immunol; 1977 Jan; 27(1):100-10. PubMed ID: 849643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Coupling proteinemia and serum protein electrophoresis: evaluation of the capillary technique (Capillarys 2, Sebia), experience from Clermont-Ferrand].
    Albert A; Gaume M; Ughetto S; Sapin V; Fogli A
    Ann Biol Clin (Paris); 2010; 68(6):657-67. PubMed ID: 21159579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.